Inhibitory effect of TGF-β peptide antagonist on the fibrotic phenotype of human hypertrophic scar fibroblasts

References

• Beanes SR, Dang C, Soo C, Ting K. (2004). Skin repair and scar formation: The central role of TGF-beta. Expert Rev Mol Med 5:1–11
   Google Scholar
• Bell E, Ivarsson B, Merrill C. (1979). Production of a tissue-like structure by contraction of collagen lattices by human fibroblasts of different proliferative potential in vitro. Proc Natl Acad Sci USA 76:1274–8
   PubMed Web of Science ®Google Scholar
• Bettinger DA, Yager DR, Diegelmann RF, Cohen IK. (1996). The effect of TGF-beta on keloid fibroblast proliferation and collagen synthesis. Plast Reconstr Surg 98:827–33
   PubMed Web of Science ®Google Scholar
• Broker BJ; Chakrabarti R, Blynman T, et al. (1999). Comparison of growth factor expression in fetal and adult fibroblasts. Arch Otolaryngol Head Neck Surg 125:676–80
   PubMedGoogle Scholar
• Chin GS, Liu W, Peled Z, et al. (2001). Differential expression of transforming growth factor-beta receptors I and II and activation of smad3 in keloid fibroblasts. Plast Reconstr Surg 108:423–9
   PubMed Web of Science ®Google Scholar
• Choi BM, Kwak HJ, Jun CD, et al. (1996). Control of scarring in adult wounds using antisense transforming growth factor-beta 1oligodeoxynucleotides. Immunol Cell Biol 74:144–50
   PubMed Web of Science ®Google Scholar
• Colas P. (2008). The eleven-year switch of peptide aptamers. J Biol 7:2
   PubMedGoogle Scholar
• Crawford M, Woodman R, Ferrigno PK. (2002). Peptide aptamers: Tools for biology and drug discovery. Brief Funct Genomics Proteomic 2:72–9
   Google Scholar
• Desmouliere A, Chaponnier C, Gabbiani G. (2005). Tissue repair, contraction, and the myofibroblast. Wound Repair Regen 13:7–12
   PubMed Web of Science ®Google Scholar
• Ehrlich HP, Diegelmann RF, Cohen K, et al. (1994). Morphological and immunochemical differences between keloid and hypertrophic scar. Am J Pathol 145:105–13
   PubMed Web of Science ®Google Scholar
• Ferguson MW, Duncan J, Bond J, et al. (2009). Prophylactic administration of avotermin for improvement of skin scarring: Three double-blind, placebo-controlled, phase I/II studies. Lancet 373:1264–74
   PubMed Web of Science ®Google Scholar
• Flechsig P, Dadrich M, Bickelhaupt S, et al. (2012). LY2109761 attenuates radiation-induced pulmonary murine fibrosis via reversal of TGF-beta and BMP-associated proinflammatory and proangiogenic signals. Clin Cancer Res 18:3616–27
   PubMed Web of Science ®Google Scholar
• Hsu M, Peled ZM, Chin GS, et al. (2001). Ontogeny of expression of transforming growth factor TGF-beta 1, 3 and TGF-beta receptors I and II in fetal rat fibroblasts and skin. Plast Reconstr Surg 107:1787–94
   PubMed Web of Science ®Google Scholar
• Huang SS, Liu QJ, Johnson FE, et al. (1997).Transforming growth factor beta peptide antagonists and their conversion to partial agonists. J Biol Chem 272:27155–9
   PubMed Web of Science ®Google Scholar
• Ignotz R, Endo T, Massague J. (1987). Regulation of fibronectin and type I collagen mRNA levels by transforming growth factor-beta. J Biol Chem 262:6443–6
   PubMed Web of Science ®Google Scholar
• John W. Lawrence JW, Fauerbach JA, Heinberg L. (2004). Visible vs hidden scars and their relation to body esteem. J Burn Care Rehabil 25:25–32
   PubMedGoogle Scholar
• Kaplan P, Anderson M, Ozanne B. (1982). Transforming growth factor(s) production enables cells to grow in the absence of serum: An autocrine system. Cell Biol 79:485–9
   Google Scholar
• Lee JY, Yang CC, Chao SC, Wong TW. (2004). Histopathological differential diagnosis of keloid and hypertrophic Scar. Am J Dermatopathol 26:379–84
   PubMed Web of Science ®Google Scholar
• Lee TY, Chin GS, Kim WJH, et al. (1999). Expression of transforming growth factor beta 1, 2 and 3 proteins in keloids. Am J Pathol 43:179–84
   Google Scholar
• Levinson H, Peled Z, Liu W, et al. (2001). Fetal rat amniotic fluid: Transforming growth factor β and fibroblast collagen lattice contraction. J surg Res 100:205–10
   PubMed Web of Science ®Google Scholar
• Liang CC, Park AY, Guan JL. (2007). In vitro scratch assay: A convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc 2:329–33
   PubMed Web of Science ®Google Scholar
• Li J, Tan S, Chen X, et al. (2011). Peptide aptamers with biological and therapeutic applications. Curr Med Chem 18:4215–22
   PubMed Web of Science ®Google Scholar
• Liu W, Chua C, Wu XL, et al. (2005). Inhibiting scar formation in rat wounds by adenovirus-mediated overexpression of truncated TGF-beta receptor II. Plast Reconstr Surg 115:860–70
   PubMed Web of Science ®Google Scholar
• Liu W, Wang DR, Cao YL. (2004). TGF-β: A fibrotic factor in wound scarring and a potential target for anti-scarring gene therapy. Curr Gene Ther 4:123–36
   PubMed Web of Science ®Google Scholar
• Melisi D, Ishiyama S, Sclabas GM, et al. (2008). LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. Mol Cancer Ther 7:829–40
   PubMed Web of Science ®Google Scholar
• Narayanan AS, Page RC, Swanson J. (1989). Collagen synthesis by human fibroblasts: Aegulation by transforming growth factor-fl in the presence of other inflammatory mediators. Biochem J 260:463–9
   PubMed Web of Science ®Google Scholar
• Newell R. (2000). Psychological difficulties amongst plastic surgery ex-patients following surgery to the face: A survey. Br J Plast Surg 53:386–92
   PubMedGoogle Scholar
• Niessen FB, Spauwen PH, Schalkwijk J, Kon M. (1999). On the nature of hypertrophic scars and keloids: A review. Plast Reconstr Surg 104:1435–58
   PubMed Web of Science ®Google Scholar
• Roberts AB, Thompson NL, Heine U, et al. (1988). Transforming growth factor-beta: Possible roles in carcinogenesis. Br J Cancer 57:594–600
   PubMed Web of Science ®Google Scholar
• Robert R, Meyer W, Bishop S, et al. (1999). Disfiguring burn scars and adolescent self-esteem. Burns 25:581–5
   PubMed Web of Science ®Google Scholar
• Schmid P, Itin P, Cherry G, et al. (1998). Enhanced expression of transforming growth factor-β3 type I and type II receptors in wound granulation tissue and hypertrophic scar. Am J Pathol 152:485–93
   PubMed Web of Science ®Google Scholar
• Shah M, Foreman DM, Ferguson MW. (1992). Control of scarring in adult wounds by neutralising antibody to transforming growth factor beta. Lancet 339:213–14
   PubMed Web of Science ®Google Scholar
• Shah M, Foreman DM, Ferguson MW. (1994). Neutralising antibody to TGF-β1,2 reduces cutaneous scarring in adult rodents. J Cell Sci 107:1137–57
   PubMed Web of Science ®Google Scholar
• Shah M, Foreman DM, Ferguson MW. (1995). Neutralisation of TGF-β1 and TGF-β2 or exogenous addition of TGF-β3 to cutaneous rat wounds reduces scarring. J Cell Sci 108:985–1002
   PubMed Web of Science ®Google Scholar
• Singer AJ, Huang SS, Huang JS, et al. (2009). A novel TGF-beta antagonist speeds reepithelialization and reduces scarring of partial thickness porcine burns. J Burn Care Res 30:329–34
   PubMed Web of Science ®Google Scholar
• Smith P, Mosiello G, Deluca L, et al. (1999). TGF-beta2 activates proliferative scar fibroblasts. J Surg Res 82:319–23
   PubMed Web of Science ®Google Scholar
• Valente SM. (2004). Visual disfigurement and depression. Plast Surg Nurs 24:140–6
   PubMedGoogle Scholar
• Verhaegen PD, van Zuijlen PP, Pennings NM, et al. (2009). Differences in collagen architecture between keloid, hypertrophic scar, normotrophic scar, and normal skin: An objective histopathological analysis. Wound Repair Regen 17:649–56
   PubMed Web of Science ®Google Scholar
• Wang RJ, Ghahary Z, Shen Q, et al. (2000). Hypertrophic scar tissues and fibroblasts produce more transforming growth factor-β1 mRNA and protein than normal skin and cells. Wound Repair Regen 8:128–37
   PubMed Web of Science ®Google Scholar
• Whitby D, Ferguson MW. (1991). The extracellular matrix of lip wounds in fetal, neonatal and adult mice. Development 112:651–68
   PubMed Web of Science ®Google Scholar
• Wolfram D, Tzankov A, Pulzl P, Piza-Katzer H. (2009). Hypertrophic scars and keloids – A review of their pathophysiology, risk factors, and therapeutic management. Dermatol Surg 35:171–81
   PubMed Web of Science ®Google Scholar
• Xu Y, Tabe Y, Jin L, et al. (2008). TGF-beta receptor kinase inhibitor LY2109761 reverses the anti-apoptotic effects of TGF-beta1 in myelo-monocytic leukaemic cells co-cultured with stromal cells. Br J Haematol 142:192–201
   PubMed Web of Science ®Google Scholar
• Yamamoto H, Ueno H, Ooshima A, Takeshita A. (1996). Adenovirus-mediated transfer of a truncated transforming growth factor-beta 2 receptors completely and specifically abolishes diverse signaling by TGF-β in vascular wall cells in primary culture. J Biol Chem 271:16253–9
   PubMed Web of Science ®Google Scholar
• Younai S, Nichter LS, Wellisz T, et al. (1994). Modulation of collagen synthesis by transforming growth factor-beta in keloid and hypertrophic scar fibroblasts. Ann Plast Surg 33:148–54
   PubMed Web of Science ®Google Scholar
• Zhang M, Kleber S, Rohrich M, et al. (2011). Blockade of TGF-beta signaling by the TGF betaR-I kinase inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma. Cancer Res 71:7155–67
   PubMed Web of Science ®Google Scholar
• Zhang Z, Garron TM, Li XJ, et al. (2009). Recombinant human decorin inhibits TGF-β1-induced contraction of collagen lattice by hypertrophic scar fibroblasts. Burns 35:527–37
   PubMed Web of Science ®Google Scholar